Journal Article

FZJ-2015-06933

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png QIAD assay for quantitating a compound’s efficacy in elimination of toxic Aβ oligomers

Brener, O. ; Dunkelmann, T.FZJ* ; Gremer, L.FZJ* ; van Groen, T. ; Mirecka, E. A. ; Kadish, I. ; Willuweit, A.FZJ* ; Kutzsche, J.FZJ* ; Jürgens, D.FZJ* ; Rudolph, S. ; Tusche, M.FZJ* ; Bongen, P.FZJ* ; Pietruszka, J.FZJ* ; Oesterhelt, F. ; Langen, K.-J.FZJ* ; Demuth, H.-U. ; Janssen, A. ; Hoyer, W.FZJ* ; Funke, S. A. ; Nagel-Steger, L.FZJ* ; Willbold, D. (Corresponding author)FZJ*

2015
Nature Publishing Group London

This record in other databases:      

Please use a persistent id in citations: http://hdl.handle.net/2128/9555  doi:10.1038/srep13222

Abstract: Strong evidence exists for a central role of amyloid β-protein (Aβ) oligomers in the pathogenesis of Alzheimer’s disease. We have developed a fast, reliable and robust in vitro assay, termed QIAD, to quantify the effect of any compound on the Aβ aggregate size distribution. Applying QIAD, we studied the effect of homotaurine, scyllo-inositol, EGCG, the benzofuran derivative KMS88009, ZAβ3W, the D-enantiomeric peptide D3 and its tandem version D3D3 on Aβ aggregation. The predictive power of the assay for in vivo efficacy is demonstrated by comparing the oligomer elimination efficiency of D3 and D3D3 with their treatment effects in animal models of Alzheimer´s disease.

---

Contributing Institute(s):

1. Strukturbiochemie (ICS-6)
2. Institut für Bioorganische Chemie (HHUD) (IBOC)
3. Biotechnologie (IBG-1)

Research Program(s):

1. 553 - Physical Basis of Diseases (POF3-553) (POF3-553)
2. 581 - Biotechnology (POF3-581) (POF3-581)

Appears in the scientific report 2015

---

Database coverage:
; ; ; ; BIOSIS Previews ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index Expanded ; Thomson Reuters Master Journal List ; Web of Science Core Collection ; Zoological Record

---